Scott Mintzer1, Rachael Miller2, Krunal Shah2, Inna Chervoneva3, Maromi Nei2, Christopher Skidmore2, Michael R Sperling2. 1. Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: scott.mintzer@jefferson.edu. 2. Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States. 3. Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States.
Abstract
BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). These studies were all of short duration, and some drugs, such as zonisamide, have not been investigated. METHODS: We recruited 41 patients taking phenytoin or carbamazepine who were being switched to zonisamide, lamotrigine, or levetiracetam. We measured serum lipids and CRP before the switch, >6weeks after, and >6months after. An untreated control group (n=14) underwent similar measurement. We combined these data with those of our previous investigation (n=34 patients and 16 controls) of a very similar design. RESULTS: There were no differences in outcome measures between the two inducing AEDs nor among the three noninducing AEDs. Total cholesterol (TC), atherogenic lipids, and CRP were higher under inducer treatment than in controls. All measures were elevated under inducer treatment relative to noninducer treatment, including TC (24mg/dL higher, 95% CI: 17.5-29.9, p<0.001) and CRP (72% higher, 95% CI: 41%-111%, p<0.001). The difference between drug treatments was clinically meaningful for atherogenic lipids (16%, 95% CI: 11%-20%, p<0.001) but small for high-density lipoprotein cholesterol (5%, 95% CI: 1%-9%, p<0.05). All measures were stable between 6weeks and 6months after drug switch. CONCLUSIONS: We demonstrate that switching from inducing to noninducing AEDs produces an enduring reduction in serum lipids and CRP. These results provide further evidence that inducing AEDs may be associated with elevated vascular disease risk. These are the first vascular risk marker data in patients taking zonisamide, which shows a profile similar to that of other noninducing AEDs.
BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). These studies were all of short duration, and some drugs, such as zonisamide, have not been investigated. METHODS: We recruited 41 patients taking phenytoin or carbamazepine who were being switched to zonisamide, lamotrigine, or levetiracetam. We measured serum lipids and CRP before the switch, >6weeks after, and >6months after. An untreated control group (n=14) underwent similar measurement. We combined these data with those of our previous investigation (n=34 patients and 16 controls) of a very similar design. RESULTS: There were no differences in outcome measures between the two inducing AEDs nor among the three noninducing AEDs. Total cholesterol (TC), atherogenic lipids, and CRP were higher under inducer treatment than in controls. All measures were elevated under inducer treatment relative to noninducer treatment, including TC (24mg/dL higher, 95% CI: 17.5-29.9, p<0.001) and CRP (72% higher, 95% CI: 41%-111%, p<0.001). The difference between drug treatments was clinically meaningful for atherogenic lipids (16%, 95% CI: 11%-20%, p<0.001) but small for high-density lipoprotein cholesterol (5%, 95% CI: 1%-9%, p<0.05). All measures were stable between 6weeks and 6months after drug switch. CONCLUSIONS: We demonstrate that switching from inducing to noninducing AEDs produces an enduring reduction in serum lipids and CRP. These results provide further evidence that inducing AEDs may be associated with elevated vascular disease risk. These are the first vascular risk marker data in patients taking zonisamide, which shows a profile similar to that of other noninducing AEDs.
Authors: Dennis R Doose; Shean-Sheng Wang; Mukund Padmanabhan; Stefan Schwabe; David Jacobs; Meir Bialer Journal: Epilepsia Date: 2003-04 Impact factor: 5.864
Authors: Scott Mintzer; Christopher T Skidmore; Sara J Rankin; Inna Chervoneva; Edward Pequinot; David M Capuzzi; Michael R Sperling Journal: Epilepsy Res Date: 2011-11-25 Impact factor: 3.045
Authors: Martin J Brodie; Scott Mintzer; Alison M Pack; Barry E Gidal; Charles J Vecht; Dieter Schmidt Journal: Epilepsia Date: 2012-09-27 Impact factor: 5.864
Authors: Scott Mintzer; Christopher T Skidmore; Caitlin J Abidin; Megan C Morales; Inna Chervoneva; David M Capuzzi; Michael R Sperling Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Anthony G Marson; Asya M Al-Kharusi; Muna Alwaidh; Richard Appleton; Gus A Baker; David W Chadwick; Celia Cramp; Oliver C Cockerell; Paul N Cooper; Julie Doughty; Barbara Eaton; Carrol Gamble; Peter J Goulding; Stephen J L Howell; Adrian Hughes; Margaret Jackson; Ann Jacoby; Mark Kellett; Geoffrey R Lawson; John Paul Leach; Paola Nicolaides; Richard Roberts; Phil Shackley; Jing Shen; David F Smith; Philip E M Smith; Catrin Tudur Smith; Alessandra Vanoli; Paula R Williamson Journal: Lancet Date: 2007-03-24 Impact factor: 79.321
Authors: Barbara C Jobst; Elinor Ben-Menachem; Kevin E Chapman; Aradia Fu; Alica Goldman; Lawrence J Hirsch; Lara E Jehi; Eric H Kossoff; Madona Plueger; Jong M Rho; Catherine A Schevon; Shlomo Shinnar; Michael R Sperling; Timothy A Simeone; Janelle L Wagner; Fred Lado Journal: Epilepsy Curr Date: 2019-05-03 Impact factor: 7.500
Authors: Jeanetta Stega; Marcus S Noel; Alexander G Vandell; Damian Stega; Giuseppe Del Priore; Steve Hoffman Journal: Invest New Drugs Date: 2019-03-30 Impact factor: 3.850
Authors: Simon Borghs; Laura Byram; Jane Chan; Peter Dedeken; John Logan; Victor Kiri; Matthias Noack-Rink; Philip N Patsalos; Solène Thieffry Journal: BMC Neurol Date: 2020-01-08 Impact factor: 2.474
Authors: Scott Mintzer; Svetlana Dimova; Ying Zhang; Björn Steiniger-Brach; Marc De Backer; Daya Chellun; Robert Roebling Journal: Epilepsia Date: 2020-11-17 Impact factor: 5.864